NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the underwriter for its recent public offering has exercised an overallotment option to purchase 825,000 additional shares of the company's common stock, bringing the total gross proceeds from the offering to $31.6 million.
Aegis Capital was the sole book-running manager on the offering. Rosetta completed the public offering of 5.5 million shares at $5 per share earlier this month.
Proceeds will go toward general corporate purposes including repayment or refinancing of debt, capital investments, and R&D and product development efforts, the Israel-based developer of microRNA-based molecular diagnostics previously said.